A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

January 19, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

December 25, 2015

Conditions
Endometrial Neoplasms
Interventions
DRUG

PF-05212384

154mg IV weekly

DRUG

PF-05212384

154mg IV weekly

DRUG

PF-05212384

154mg IV weekly

Trial Locations (51)

3002

Peter MacCallum Cancer Centre, Division of Cancer Madicine, East Melbourne

28033

Centro Oncologico MD Anderson Internacional España, Madrid

28040

Hospital Clinico San Carlos, Madrid

28046

Hospital Universitario La Paz, Madrid

33133

Mercy Hospital, Miami

Mercy Research Institute, Miami

35233

University of Alabama at Birmingham, Birmingham

35249

University of Alabama at Birmingham, IDS Pharmacy, Birmingham

University of Alabama at Birmingham, Birmingham

46009

Fundacion Instituto Valenciano de Oncologia - I.V.O., Valencia

Fundacion Instituto Valenciano de Oncologia - I.V.O, Valencia

48109

University of Michigan, Ann Arbor

60451

University of Chicago Medicine Comprehensive Cancer Center at Silver Cross Hospital, New Lenox

60637

University of Chicago Medical Center, Chicago

66160

University of Kansas Hospital, Kansas City

66205

University of Kansas, Fairway

University of Kansas Cancer Center and Medical Pavilion, Westwood

70006

Women's Cancer Care, Metairie

70433

Mary Bird Perkins Cancer Center at St. Tammany Parish Hospital, Covington

Women's Cancer Care, Covington

87106

University of New Mexico Cancer Center, Albuquerque

92037

University of California Medical Center, La Jolla

92093

Moores UC San Diego Cancer Center, La Jolla

92103

University of California Medical Center, San Diego

198255

Saint Petersburg State Healthcare Institution City Clinical Oncology Dispensary, Saint Petersburg

350040

Clinical Oncology Dispensary 1 of Department of Healthcare of the Krasnodar Region, Krasnodar

357340

Federal State Healthcare Institution, Lermontov

357502

Pyatigorsk Oncology Center, Pyatigorsk

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

T2N 2T9

Foothills Medical Center, Calgary

T2N 4N2

Tom Baker Cancer Centre, Calgary

V5Z 4E6

British Columbia Cancer Agency - Vancouver Centre, Vancouver

K7L 5P9

Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston

M5G 2M9

Princess Margaret Hospital, Toronto

H3A 1A1

Royal Victoria Hospital, Montreal

H3T 1E2

Jewish General Hospital, Montreal

H3T 1M5

St. Mary's Hospital, Montreal

464-8681

Aichi cancer center hospital, Nagoya

673-8558

Hyogo Cancer Center, Akashi

350-1298

Saitama Medical University International Medical Center, Hidaka

104-0045

National Cancer Center Hospital, Chuo-Ku

93-509

Regionalny Osrodek Onkologiczny Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Lodz

93-513

Zaklad Radiologii, Lodz

20-090

Centrum Onkologii Ziemi Lubelskiej im. Św. Jana z Dukli, Lublin

08035

Hospital Universitari Vall d'hebron, Barcelona

SM2 5PT

The Royal Marsden NHS Foundation Trust, Sutton

G12 0YN

Beatson Oncology Centre, Glasgow

NW1 2PG

University College London Hospital NHS Foundation Trust, London

SW3 6JJ

The Royal Marsden NHS Foundation Trust, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY